163P Health-related quality of life (HRQoL) with pembrolizumab (pembro) vs chemotherapy (chemo) in platinum-pretreated recurrent or metastatic (R/M) nasopharyngeal cancer (NPC): Phase III KEYNOTE-122 study
2021; Elsevier BV; Volume: 32; Linguagem: Inglês
10.1016/j.annonc.2021.10.182
ISSN1569-8041
AutoresAnthony T.�C. Chan, H.F.V. Lee, R-L. Hong, M-J. Ahn, Wan Qin Chong, S-B Kim, Gwo Fuang Ho, Priscilla B. Caguioa, Nuttapong Ngamphaiboon, Gwo Fuang Ho, M.A.S. Abdul Aziz, Quan Sing Ng, Chia‐Jui Yen, Nopadol Soparattanapaisarn, Roger K.C. Ngan, S.K. Kho, L. Wang, Ramona F. Swaby, Sanatan Saraf, Lillian L. Siu,
Tópico(s)Cancer Immunotherapy and Biomarkers
ResumoPembro did not improve OS vs chemo in patients (pts) with platinum-pretreated R/M NPC in KEYNOTE-122 (NCT02611960), but it had manageable safety and fewer treatment-related AEs. HRQoL results are shown.
Referência(s)